-
Promising New Treatment for Portopulmonary Hypertension
The results of a Phase 4 clinical study suggest that Actelion’s Opsumit may be a therapeutic option for patients with portopulmonary hypertension. Read the full story here.
What do you think about the study and its results?
Sorry, there were no replies found.
Log in to reply.